[1] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[2] |
YUE Xiaolin, LU Song, ZHANG Lan.
Research in the construction of comprehensive evaluation systems of drugs in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 530-535.
|
[3] |
LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping.
Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
|
[4] |
LIU Jing, LIU Yan, ZHENG Xiaowei, WANG Qi, HE Fengyan, WANG Feifei, WANG Yadan, HE Yi, NIE Lixing, HU Xiaoru, DAI Zhong, MA Shuangcheng.
Quality analysis of Guci tablets based on national drug evaluation sampling
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 292-295.
|
[5] |
GAO Jing, ZHANG Zhuo, YAN Jiayi, GE Yunxuan, MA Zengchun, GAO Yue.
Evaluation of animal models of high altitude qi deficiency and blood stasis syndrome and research progress in therapeutic drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1189-1194.
|
[6] |
JIANG Jiandong.
Development and clinical safety of paediatric medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 1-6.
|
[7] |
WANG Juli, ZHANG Xiaomeng, ZHANG Bing, LYU Jintao.
Safety of medications for cardiovascular diseases in community clinics
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 744-748.
|
[8] |
LU Song, YANG Ping, YANG Li, DONG Xianzhe, ZHANG Lan.
Research progress in human serum albumin injections
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 228-232.
|
[9] |
HUANG Liting, TANG Zaixiang, BAI Lu, SHI Guanhong, JIANG Yiguo.
Adverse reactions of benzodiazepines based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1223-1227.
|
[10] |
WU Yingqi, ZHU Ting, TONG Tong, LI Min, SHEN Aizong.
Factors related to ADR/ADE of albumin bound paclitaxel
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1123-1127.
|
[11] |
WANG Wen, LIU Mei, HE Qiao, TIAN Chunhua, SONG Haibo, WANG Tao, TAN Jing, REN Yan, GAO Pei, PENG Xiaoxia, WEN Zehuai, SHU Xiaochen, ZOU Kang, SHEN Chuanyong, SUN Xin.
Expert consensus on design and statistical analysis to evaluate drug safety using routinely collected health data
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 7-12.
|
[12] |
ZHANG Dan, LYU Jintao, SONG Haibo, ZHANG Bing, JIN Yongnan, SA Rina, ZHANG Xiaomeng, LIN Zhijian.
Drug Risk Communication among Drug Regulatory Agencies in the European Union, the United States and Asia
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 845-849.
|
[13] |
MENG Ruogu, ZHUO Lin, QIAO Rui, LIU Yuqiang, SUN Feng, ZHAN Siyan.
Application Values of Real-World Evidence in Post-Marketing Surveillances and Evaluation for Drug Safety
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 624-627.
|
[14] |
LI Jiayi, GE Feilin, CAO Junling, ZHOU Xiaochun, GAO Yunjuan, MU Guangdi, ZHAO Xu, CAO Boya, GUO Yuming.
Clinical Characteristics and Rationality of Drug Usage in Antibiotic Agents Related Liver Injury
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1020-1024.
|
[15] |
XUE Xue, JIN Xinyan, LU Chunli, DAI Ning, LIU Jianping.
Application of Real-World Study Designs in Post-Marketing Evaluation of Drug Safety
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1025-1028.
|